1. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy
- Author
-
Arnaud Lacour, Frédéric Blanc, Hélène Zéphir, Nicolas Collongues, Patrick Vermersch, Anne-Sophie Berteloot, Jean-Claude Ongagna, Marie-Céline Fleury, Marianne Giroux, Alain Duhamel, Olivier Outteryck, and Jérôme De Seze
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multiple Sclerosis ,Adolescent ,viruses ,Antibodies, Monoclonal, Humanized ,Antibodies, Viral ,Cohort Studies ,Young Adult ,Natalizumab ,Internal medicine ,Prevalence ,Humans ,Medicine ,Young adult ,Risk factor ,Aged ,biology ,business.industry ,Progressive multifocal leukoencephalopathy ,Multiple sclerosis ,Leukoencephalopathy, Progressive Multifocal ,virus diseases ,Middle Aged ,medicine.disease ,JC Virus ,Neurology ,Cohort ,Immunology ,biology.protein ,Female ,France ,Neurology (clinical) ,Antibody ,business ,medicine.drug ,Cohort study - Abstract
To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.
- Published
- 2012